血管紧张素 II 受体与心血管疾病相关药物研发
Angiotensin II receptors and drug discovery in cardiovascular disease.
机构信息
Fetal-Origin Diseases Institute, First Affiliated Hospital of Soochow University, Suzhou 215000, China.
出版信息
Drug Discov Today. 2011 Jan;16(1-2):22-34. doi: 10.1016/j.drudis.2010.11.016. Epub 2010 Dec 13.
Abstract
Hypertension is one of the cardiovascular diseases that might cause cardiovascular remodeling and endothelial dysfunction besides high blood pressure. Angiotensin II (Ang II) receptors are implicated in hypertension. Genetic and epigenetic manipulations of the Ang II receptors play a crucial part in the programming of cardiovascular diseases, and certain variants of the Ang II type 1 and Ang II type 2 receptors are constitutively predisposed to higher cardiovascular risk and hypertension. In this review, we focus on the expression, mode of action of Ang II receptors, and their role in programming the cardiovascular diseases in utero. In addition, we discuss possible therapeutic interventions of Ang II stimulation. Collectively, this information might lead us to new drug designs against cardiovascular diseases.
摘要
高血压是心血管疾病之一，除了高血压外，还可能导致心血管重构和内皮功能障碍。血管紧张素 II（Ang II）受体与高血压有关。Ang II 受体的遗传和表观遗传操作在心血管疾病的编程中起着至关重要的作用，某些 Ang II 类型 1 和 Ang II 类型 2 受体的变体先天倾向于更高的心血管风险和高血压。在这篇综述中，我们重点讨论了 Ang II 受体的表达、作用模式及其在子宫内编程心血管疾病中的作用。此外，我们还讨论了 Ang II 刺激的可能治疗干预措施。总的来说，这些信息可能会促使我们设计出针对心血管疾病的新药。
相似文献
1
Angiotensin II receptors and drug discovery in cardiovascular disease.血管紧张素 II 受体与心血管疾病相关药物研发
Drug Discov Today. 2011 Jan;16(1-2):22-34. doi: 10.1016/j.drudis.2010.11.016. Epub 2010 Dec 13.
2
Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.心脏特异性过表达血管紧张素II AT2受体可导致对AT1受体介导的升压和变时作用的反应减弱。
J Clin Invest. 1998 Feb 1;101(3):527-35. doi: 10.1172/JCI1885.
3
Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases.局部肾素-血管紧张素-醛固酮系统与心血管疾病。
Med Clin North Am. 2017 Jan;101(1):117-127. doi: 10.1016/j.mcna.2016.08.017.
4
Angiotensin II receptors in endothelial cells.内皮细胞中的血管紧张素II受体。
Gen Pharmacol. 1997 Nov;29(5):691-6. doi: 10.1016/s0306-3623(97)00021-9.
5
Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19.血管紧张素 II 及其受体阻滞剂的受体相互作用与 COVID-19 的相关性。
Biomolecules. 2021 Jul 3;11(7):979. doi: 10.3390/biom11070979.
6
Modulation and function of extrarenal angiotensin receptors.肾外血管紧张素受体的调节与功能
Cell Biochem Biophys. 1999;31(1):1-17. doi: 10.1007/BF02738152.
7
The renin-angiotensin system and its receptors.肾素-血管紧张素系统及其受体。
J Cardiovasc Pharmacol. 1999;33 Suppl 1:S21-8; discussion S41-3. doi: 10.1097/00005344-199900001-00005.
8
Role of the renin-angiotensin system in cardiovascular disease.肾素-血管紧张素系统在心血管疾病中的作用。
Cardiovasc Drugs Ther. 2010 Aug;24(4):341-4. doi: 10.1007/s10557-010-6230-3.
9
Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function.心力衰竭临床过程中心脏局部血管紧张素II的生成及其与左心室功能的关系。
Circ Res. 2001 May 11;88(9):961-8. doi: 10.1161/hh0901.089882.
10
Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.通过血管紧张素转换酶抑制和AT1受体拮抗作用对肾小球血管紧张素II受体的调节。
Regul Pept. 1997 Jan 29;68(2):111-7. doi: 10.1016/s0167-0115(96)02112-x.
引用本文的文献
1
ML enhanced bioactivity prediction for angiotensin II receptor: A potential anti-hypertensive drug target.机器学习增强血管紧张素II受体的生物活性预测：一种潜在的抗高血压药物靶点。
Sci Rep. 2025 Jul 14;15(1):25367. doi: 10.1038/s41598-025-08653-4.
2
Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease.多囊肾病中的纤毛G蛋白偶联受体信号传导
Int J Mol Sci. 2025 May 22;26(11):4971. doi: 10.3390/ijms26114971.
3
A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.靶向肾素-血管紧张素-醛固酮系统的小分子及其在心血管疾病中的应用前景：探索合理药物发现与开发的结构见解
RSC Med Chem. 2025 Jan 21. doi: 10.1039/d4md00720d.
4
The Role of Chronic Stress in the Pathogenesis of Ischemic Heart Disease in Women.慢性应激在女性缺血性心脏病发病机制中的作用
Compr Physiol. 2025 Feb;15(1):e70000. doi: 10.1002/cph4.70000.
5
Cross-Section of Hypertensive Molecular Signaling Pathways: Understanding Pathogenesis and Identifying Improved Drug Targets.高血压分子信号通路的横断面：理解发病机制与确定改进的药物靶点
Curr Hypertens Rev. 2025;21(1):31-44. doi: 10.2174/0115734021342501250107052350.
6
Location-biased β-arrestin conformations direct GPCR signaling.定位偏向性β-抑制蛋白构象指导G蛋白偶联受体信号传导。
bioRxiv. 2024 Sep 26:2024.09.24.614742. doi: 10.1101/2024.09.24.614742.
7
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation.通过糖基化调节可溶性血管紧张素转换酶2诱饵受体的药代动力学。
Mol Ther Methods Clin Dev. 2024 Jul 19;32(3):101301. doi: 10.1016/j.omtm.2024.101301. eCollection 2024 Sep 12.
8
Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response.杜氏肌营养不良症中的心肌病和线粒体治疗药物改善治疗反应的潜力。
Cells. 2024 Jul 9;13(14):1168. doi: 10.3390/cells13141168.
9
Advancements in the neurocirculatory reflex response to hypoxia.神经循环反射对缺氧反应的研究进展。
Am J Physiol Regul Integr Comp Physiol. 2024 Jul 1;327(1):R1-R13. doi: 10.1152/ajpregu.00237.2023. Epub 2024 May 13.
10
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?SGLT2 抑制剂为何未能在 COVID-19 中取得预期的成功？
Curr Pharm Des. 2024;30(15):1149-1156. doi: 10.2174/0113816128300162240322075423.
本文引用的文献
1
Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury.胎儿缺氧会增加心脏 AT(2)R 的表达，从而使其在成年后更容易受到缺血性损伤。
Cardiovasc Res. 2011 Feb 1;89(2):300-8. doi: 10.1093/cvr/cvq303. Epub 2010 Sep 23.
2
Developmental changes in AT1 and AT2 receptor-protein expression in rats.大鼠 AT1 和 AT2 受体蛋白表达的发育变化。
J Renin Angiotensin Aldosterone Syst. 2010 Dec;11(4):214-21. doi: 10.1177/1470320310379065. Epub 2010 Aug 31.
3
Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus.血管紧张素-(1-12)在孤束核内发挥心血管作用需要血管紧张素转换酶和 AT1 受体。
Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H763-71. doi: 10.1152/ajpheart.00345.2010. Epub 2010 Jun 18.
4
5
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.ANG-(1-7)/ACE2/mas 轴在肾单位功能调节中的作用。
Am J Physiol Renal Physiol. 2010 Jun;298(6):F1297-305. doi: 10.1152/ajprenal.00110.2010. Epub 2010 Apr 7.
6
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.血管紧张素转换酶与心血管疾病的药物研发。
Drug Discov Today. 2010 May;15(9-10):332-41. doi: 10.1016/j.drudis.2010.02.003. Epub 2010 Feb 17.
7
Endothelial dysfunction: a strategic target in the treatment of hypertension?内皮功能障碍：高血压治疗的策略靶点？
Pflugers Arch. 2010 May;459(6):995-1004. doi: 10.1007/s00424-010-0786-4. Epub 2010 Feb 2.
8
New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.从血管紧张素I代谢前体和产物的研究中得出的肾素-血管紧张素系统新的生理学概念。
Hypertension. 2010 Feb;55(2):445-52. doi: 10.1161/HYPERTENSIONAHA.109.145839. Epub 2009 Dec 21.
9
The biology of the (pro)renin receptor.（原）肾素受体的生物学特性。
J Am Soc Nephrol. 2010 Jan;21(1):18-23. doi: 10.1681/ASN.2009030300. Epub 2009 Nov 16.
10
The angiotensin II type 2 receptor in cardiovascular disease.血管紧张素 II 型受体在心血管疾病中的作用。
J Renin Angiotensin Aldosterone Syst. 2010 Mar;11(1):19-31. doi: 10.1177/1470320309347785. Epub 2009 Oct 27.
Zotero 插件